Carbamazepine (Epilepsy)

Macrosomia (> 4000g)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S10075
R36694		 Coste (Carbamazepine), 2020 Weight at birth (≥3500 g) during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick Adjustment: No 1.08 [0.78;1.50] C 57/176   648/2,108 705 176
ref
S7181
R20255		 Kini (Carbamazepine) (Controls unexposed, sick), 2006 Birth weight >4000 g during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No 0.88 [0.36;2.15] C 10/94   12/101 22 94
ref
S8223
R25775		 Endo (Carbamazepine) (Controls unexposed, sick), 2004 Birth weight > 4,000g throughout pregnancy retrospective cohort unexposed, sick Adjustment: No 0.07 [0.00;8.55] C 0/8   0/1 0 8
ref
Total 3 studies 1.04 [0.77;1.42] 727 278
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Coste (Carbamazepine), 2020Coste, 2020 1 1.08[0.78; 1.50]70517688%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: moderateROB mesure: moderateROB reporting: moderate Kini (Carbamazepine) (Controls unexposed, sick), 2006Kini, 2006 2 0.88[0.36; 2.15]229412%ROB confusion: criticalROB selection: criticalROB classification: lowROB missing: unclearROB mesure: moderateROB reporting: moderate Endo (Carbamazepine) (Controls unexposed, sick), 2004Endo, 2004 3 0.07[0.00; 8.55]080%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 0% 1.04[0.77; 1.42]7272780.05.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Carbamazepine; 2: Carbamazepine) (Controls unexposed, sick; 3: Carbamazepine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.04[0.77; 1.42]7272780%NACoste (Carbamazepine), 2020 Kini (Carbamazepine) (Controls unexposed, sick), 2006 Endo (Carbamazepine) (Controls unexposed, sick), 2004 3 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.76[0.24; 2.45]221025%NAKini (Carbamazepine) (Controls unexposed, sick), 2006 Endo (Carbamazepine) (Controls unexposed, sick), 2004 2 exposed to other treatment, sickexposed to other treatment, sick 1.08[0.78; 1.50]705176 -NACoste (Carbamazepine), 2020 1 Tags Adjustment   - No  - No 1.04[0.77; 1.42]7272780%NACoste (Carbamazepine), 2020 Kini (Carbamazepine) (Controls unexposed, sick), 2006 Endo (Carbamazepine) (Controls unexposed, sick), 2004 3 All studiesAll studies 1.04[0.77; 1.42]7272780%NACoste (Carbamazepine), 2020 Kini (Carbamazepine) (Controls unexposed, sick), 2006 Endo (Carbamazepine) (Controls unexposed, sick), 2004 30.05.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 0.76[0.24; 2.45]221025%NAKini (Carbamazepine) (Controls unexposed, sick), 2006 Endo (Carbamazepine) (Controls unexposed, sick), 2004 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.08[0.78; 1.50]705176 -NACoste (Carbamazepine), 2020 10.510.01.0